BioVersys Doses First Patient in Phase 2b AlpE Pulmonary TB Trial
13 Mar 2026 //
GLOBENEWSWIRE
Bioversys Initiates BV100 Phase 3 Trial, Issues Business Update
11 Dec 2025 //
GLOBENEWSWIRE
BioVersys Granted EMA Orphan Status for Alpibectir & Ethionamide
27 Aug 2025 //
GLOBENEWSWIRE

Market Place
Sourcing Support